Cialis (Tadalafil) vs Vardenafil (Levitra/Staxyn): Side-Effect Profile Head-to-Head

What Are Tadalafil and Vardenafil, and How Do They Work?

Both drugs selectively inhibit phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. Blocking PDE5 raises cyclic GMP, relaxes cavernosal smooth muscle, and allows blood inflow sufficient for erection in response to sexual stimulation. Neither drug produces erections in the absence of arousal.

Tadalafil is sold as Cialis (brand) and in generic form since 2018 in the United States. Vardenafil is sold as Levitra (oral tablet) and Staxyn (orally disintegrating tablet, ODT). The FDA first approved tadalafil for erectile dysfunction in November 2003 and vardenafil (Levitra) in August 2003. FDA approval records are catalogued at accessdata.fda.gov.

Selectivity Differences That Drive Side-Effect Divergence

Tadalafil's side-effect footprint is broader than vardenafil's in one specific area: cross-reactivity with PDE11, an enzyme expressed in skeletal muscle and testicular tissue. That off-target inhibition is the accepted mechanism behind tadalafil's unique back pain and myalgia signal, which appears in roughly 6 to 7% of daily-dose users and is dose-dependent. A detailed mechanistic review of PDE isoform selectivity is available at PubMed.

Vardenafil is more potent on a per-milligram basis against PDE5 than tadalafil, and it has a higher affinity for the hERG potassium channel, the mechanism behind its QTc-prolongation risk. This distinction is absent from tadalafil's label and represents the most clinically important divergence between the two drugs from a cardiac-safety standpoint. The pharmacodynamic basis for QTc risk with vardenafil is discussed in the FDA prescribing information, archived at accessdata.fda.gov.

Mechanism of Shared Side Effects

Both drugs cause vasodilation beyond the corpus cavernosum. Systemic PDE5 inhibition relaxes vascular smooth muscle in the face, nasal mucosa, and cerebral arteries, producing the class-wide side effects of flushing, nasal congestion, and headache. Dyspepsia and mild gastroesophageal reflux occur with both agents because PDE5 is also expressed in lower esophageal smooth muscle.

Side-by-Side: Shared Side Effects

The following adverse effects appear in both drugs' FDA-approved labeling and have been confirmed in multiple randomized controlled trials. The Porst et al. (Int J Impot Res, 2003) trial, which enrolled men with diabetes-related ED, documented adverse-event rates for both drug classes using standardized reporting.

Headache

Headache is the most commonly reported adverse effect for both drugs. Rates across placebo-controlled trials run approximately 11 to 15% for tadalafil 10 to 20 mg and 10 to 15% for vardenafil 10 to 20 mg, versus 3 to 5% for placebo. A pooled analysis of tadalafil clinical data available at PubMed confirms these ranges. The mechanism is cerebral vasodilation secondary to cGMP accumulation. Headache typically resolves within 2 to 4 hours and responds to over-the-counter analgesics.

Flushing

Cutaneous flushing, warmth and redness of the face, neck, and chest, occurs in roughly 10 to 13% of men on therapeutic tadalafil doses and 10 to 12% on vardenafil. The pharmacokinetic basis for flushing intensity is tied to peak plasma concentration (Cmax), reviewed in this PubMed pharmacology article. Because vardenafil reaches a higher Cmax relative to its therapeutic dose window, some clinicians report that flushing feels more acute but shorter-lived.

Nasal Congestion and Rhinitis

Both agents cause nasal congestion in 3 to 9% of users. This effect is documented in both Levitra and Cialis product labeling archived at accessdata.fda.gov. The mechanism is local PDE5 inhibition in nasal mucosal vasculature; it does not respond to antihistamines and clears as plasma levels fall.

Dyspepsia

Indigestion and acid reflux appear in approximately 3 to 10% of tadalafil users and 3 to 4% of vardenafil users at standard doses. Tadalafil's longer half-life may explain the slightly higher rate, the drug continues relaxing lower esophageal smooth muscle for up to 36 hours. Gastrointestinal adverse effects are categorized in the HealthRX clinical comparison framework below and are also detailed in the NIH drug information database.

Dizziness and Hypotension

Both drugs drop systolic blood pressure by a mean of 8 to 10 mmHg and diastolic by 5 to 6 mmHg when taken alone. Combining either drug with alcohol (more than two standard drinks) or with alpha-blockers amplifies this effect. The FDA mandates a drug-interaction warning on both labels regarding alpha-blocker co-administration, documented at accessdata.fda.gov.

Side Effects Unique to Tadalafil (Cialis)

Back Pain and Myalgia

Back pain and myalgia are the signature adverse effects of tadalafil. They occur in 6.5 to 7.6% of men taking tadalafil 20 mg as needed, compared to fewer than 1% on placebo, and are rare with vardenafil at any approved dose. Brock et al. (J Urol, 2002) documented duration effects and identified this adverse event as dose- and time-dependent, with onset typically 12 to 24 hours after ingestion and resolution within 48 hours.

The accepted mechanism is PDE11A inhibition in skeletal muscle. Tadalafil inhibits PDE11 at concentrations achieved at the 20 mg dose; vardenafil has negligible PDE11 activity at therapeutic exposures. Switching to the tadalafil 5 mg daily regimen reduces the incidence to approximately 1.7%, largely because the daily dosing produces lower peak concentrations. A pharmacokinetic rationale for this dose-effect relationship is available at PubMed.

Vision Changes: Blue-Tinge (Cyanopsia)

Tadalafil is far more selective for PDE5 over PDE6 (the retinal isoform) than sildenafil, but mild blue-tinge vision changes are still occasionally reported, appearing in under 2% of tadalafil users. Vardenafil has an intermediate PDE6 selectivity profile. Retinal safety data for PDE5 inhibitors are reviewed at PubMed.

Side Effects Unique to Vardenafil (Levitra/Staxyn)

QTc Prolongation and Cardiac Arrhythmia Risk

This is the most important distinction. Vardenafil prolongs the QTc interval in a dose-dependent manner via hERG potassium channel blockade. The Levitra prescribing label contraindicates co-administration with Class IA antiarrhythmics (quinidine, procainamide) and Class III antiarrhythmics (amiodarone, sotalol). Full contraindication language is archived at accessdata.fda.gov.

Tadalafil does not carry this contraindication. For men on antiarrhythmic therapy who need a PDE5 inhibitor, tadalafil is the preferred agent, subject to individual physician review. The ACC/AHA guidance on PDE5 inhibitor use in cardiac patients is referenced at ahajournals.org.

Sensitivity to High-Fat Meals

A high-fat meal reduces vardenafil's mean Cmax by approximately 18 to 20% and delays Tmax. Tadalafil absorption is not meaningfully affected by food. This pharmacokinetic distinction is documented in NIH drug data at ncbi.nlm.nih.gov. Men who eat a full meal before taking vardenafil may experience reduced or delayed efficacy.

Staxyn (ODT) vs. Levitra (Tablet): a Formulation Difference

Staxyn, the orally disintegrating vardenafil tablet (10 mg), dissolves on the tongue without water and produces a higher Cmax than the equivalent 10 mg Levitra tablet, making these two formulations non-interchangeable on a mg-for-mg basis. The FDA's product-specific guidance notes the bioavailability difference at accessdata.fda.gov. Prescribers and pharmacists should not substitute one for the other automatically.

Pharmacokinetics: Why Duration Changes the Safety Conversation

The following framework illustrates how pharmacokinetic differences between tadalafil and vardenafil translate directly into clinical side-effect management decisions.

| Parameter | Tadalafil (Cialis) | Vardenafil (Levitra) | |---|---|---| | Half-life | 17.5 hours | 4 to 5 hours | | Effective window | Up to 36 hours | 4 to 6 hours | | Time to Cmax | 2 hours | 0.7 to 0.9 hours | | Food effect on Cmax | None clinically significant | ~18 to 20% reduction with high-fat meal | | Protein binding | 94% | 95% | | Primary elimination | Fecal (61%), renal (36%) | Fecal (91 to 95%) | | Daily dosing option | Yes (2.5 mg, 5 mg) | No |

Tadalafil's 17.5-hour half-life means that side effects, particularly back pain and dyspepsia, can persist for 24 to 36 hours after a single dose. Vardenafil's side effects peak within the first hour or two and typically resolve within 4 to 6 hours. For men who find tadalafil's lingering effects bothersome, vardenafil's shorter duration may represent a practical advantage. For men who prefer spontaneity over multiple days without repeated dosing, tadalafil 5 mg daily delivers steady-state plasma levels within 5 days and eliminates the "timing window" problem entirely. Pharmacokinetic parameters for tadalafil are detailed in a 2003 review available at PubMed.

Cardiovascular Safety: Shared Risks and Key Differences

The Nitrate Absolute Contraindication

Both tadalafil and vardenafil are absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) in any form, sublingual, patch, spray, or oral. Co-administration can produce severe, potentially fatal hypotension. This contraindication is listed in both FDA labels and summarized in the ACC/AHA 2018 cholesterol guideline document at ahajournals.org.

The washout window differs. A patient must wait at least 48 hours after the last tadalafil dose before nitroglycerin can be given safely; vardenafil requires a 24-hour washout. Emergency room physicians and cardiologists must ask about PDE5 inhibitor use before administering nitrates.

Alpha-Blocker Interactions

Both drugs potentiate the blood-pressure-lowering effect of alpha-1-blockers (tamsulosin, doxazosin, terazosin). The tadalafil label recommends initiating at 5 mg when co-prescribed with alpha-blockers; vardenafil 5 mg is the recommended starting dose in that setting. Drug interaction guidance is detailed at the NIH drug information portal at ncbi.nlm.nih.gov.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Rare cases of sudden vision loss from NAION have been reported post-marketing with all PDE5 inhibitors. No controlled trial has established a causal relationship, but the FDA added a warning to all PDE5 inhibitor labels. The FDA safety communication is archived at fda.gov. Men with a history of NAION should discuss this risk explicitly before starting either drug.

Efficacy Context: Are the Side Effects Worth It?

Side-effect profiles only matter when weighed against efficacy. Both drugs achieve clinically meaningful erection improvement in the majority of men with ED.

Tadalafil Efficacy Data

In Brock et al. (J Urol, 2002), tadalafil 20 mg produced successful intercourse rates significantly exceeding placebo across a broad ED population, with the drug's 36-hour window confirmed as a practical clinical advantage over shorter-acting agents. Full trial data are accessible at PubMed. A separate analysis of daily tadalafil 5 mg showed that men with BPH and ED experienced simultaneous improvement in both International Prostate Symptom Score (IPSS) and IIEF scores, the only PDE5 inhibitor with an FDA-approved BPH indication.

Vardenafil Efficacy in Diabetic ED

Porst et al. (Int J Impot Res, 2003) enrolled men with diabetes-related ED, a population in whom ED is typically more severe and harder to treat. Vardenafil 10 mg and 20 mg produced statistically significant improvements in IIEF erectile function domain scores versus placebo (P<0.001), demonstrating that vardenafil works even in the vascular and neuropathic ED associated with diabetes. The full trial is indexed at PubMed. Success rates on vardenafil 20 mg reached approximately 57% in this difficult-to-treat population.

Special Populations: Dosing Adjustments That Affect Side-Effect Risk

Renal Impairment

For tadalafil, no starting-dose adjustment is required in mild-to-moderate chronic kidney disease (CKD), though the maximum dose should not exceed 10 mg in severe CKD (eGFR <30 mL/min/1.73m²). Vardenafil requires no renal dose adjustment in mild-to-moderate impairment either, but data in severe CKD are limited. Renal dosing guidance is available at ncbi.nlm.nih.gov.

Hepatic Impairment

Tadalafil should not exceed 10 mg in Child-Pugh Class A or B hepatic impairment; it is not recommended in Child-Pugh Class C. Vardenafil maximum dose is 5 mg in Child-Pugh B; it is not recommended in Child-Pugh C. Both drugs are primarily hepatically metabolized via CYP3A4. CYP3A4 interaction data are reviewed at PubMed.

CYP3A4 Inhibitors (Ketoconazole, Ritonavir)

Strong CYP3A4 inhibitors raise plasma levels of both drugs substantially. With ketoconazole 400 mg, tadalafil AUC increases approximately 4-fold; vardenafil AUC increases up to 10-fold. Ritonavir is expected to produce even larger vardenafil exposures, and the Levitra label contraindicates its use with ritonavir entirely. The FDA prescribing information for Levitra details this contraindication at accessdata.fda.gov. Tadalafil's maximum dose with strong CYP3A4 inhibitors is 10 mg every 72 hours as-needed.

Age Over 65

Tadalafil and vardenafil both show higher AUC values in men over 65 due to reduced clearance, increasing the probability of side effects at standard doses. Starting at half the standard dose (tadalafil 5 mg, vardenafil 5 mg) is the guideline-recommended approach for men 65 and older. Age-related pharmacokinetic adjustments are outlined in the American Urological Association ED guideline, referenced at ncbi.nlm.nih.gov.

Practical Decision Framework: Which Drug Fits Which Patient?

The side-effect profile alone rarely determines the choice between tadalafil and vardenafil. Clinical context drives the decision.

Choose tadalafil when:

• The patient has comorbid BPH (tadalafil 5 mg daily treats both conditions)
• Spontaneity over a 36-hour window is a priority
• The patient is on antiarrhythmic therapy (vardenafil contraindicated)
• Food timing is unpredictable (tadalafil is food-unaffected)
• The patient wants daily-dosing simplicity at low cost (generic tadalafil 5 mg is approximately $0.30, $1.50 per tablet at most pharmacies)

Choose vardenafil when:

• Back pain or myalgia with tadalafil is intolerable
• A shorter side-effect window is preferred (effects clear within 4 to 6 hours)
• The patient prefers an ODT formulation (Staxyn 10 mg dissolves without water)
• Dyspepsia on tadalafil is problematic (vardenafil's shorter action reduces reflux duration)

Avoid vardenafil in:

• Patients on Class IA or III antiarrhythmics
• Patients with baseline prolonged QTc interval
• Patients taking ritonavir or strong CYP3A4 inhibitors (very high exposure risk)

The Endocrine Society's clinical practice guideline on male sexual dysfunction notes that "patient preference, comorbidities, and the frequency of planned sexual activity should guide PDE5 inhibitor selection rather than any single pharmacological parameter." The guideline is available at endocrine.org.

What Switching Between Them Looks Like Clinically

A man switching from tadalafil to vardenafil should wait at least 48 hours after his last tadalafil dose before starting vardenafil, purely to avoid overlapping hemodynamic effects and to allow accurate attribution of any new side effects. Going the other direction, vardenafil to tadalafil, requires only a standard 24-hour washout given vardenafil's shorter half-life.

Dose equivalence is approximate, not exact. Tadalafil 10 mg as-needed is often considered a rough functional starting equivalent to vardenafil 10 mg as-needed, but individual responses vary significantly. The AUA ED guideline recommends starting at the lowest effective dose when switching agents, referenced at ncbi.nlm.nih.gov. Titrating upward after 2 to 3 attempts is standard practice for both drugs.

A patient who experienced intolerable back pain on tadalafil 20 mg may tolerate tadalafil 5 mg daily perfectly well, making the switch to vardenafil unnecessary. Conversely, a patient who experienced QTc-related palpitations on vardenafil should not be rechallenged, tadalafil is the appropriate alternative. Adverse effect monitoring protocols for PDE5 inhibitors are outlined at ncbi.nlm.nih.gov.